Active • Host: HEK293 cells • AA: 2-215 (full length) • Tag: C-terminal His • MW: 26.21 kDa
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

HMGB1 (human, recombinant)

Item No. 43701

Product Insert (PDF)
Technical Information
Synonyms
  • Amphoterin
  • High-mobility Group Box 1 Protein
  • High Mobility Group Protein B1
  • HMG-1
  • SBP-1
Purity
≥95% as estimated by SDS-PAGE
Endotoxin Testing
<1.0 EU/μg, determined by the LAL endotoxin assay
Source
Active recombinant human C-terminal His-tagged HMGB1 expressed in HEK293 cells
Amino Acids
2-215 (full length)
MW
26.21 kDa
Formulation (Request formulation change)
Lyophilized from sterile PBS, pH 7.4, 5%, with trehalose, 5% mannitol, and 0.01% polysorbate 80
UniProt Accession №
P09429
Shipping & Storage Information
Storage
-80°C
Shipping
Dry ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    100 µg

    $383

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    High mobility group protein B1 (HMGB1) is a member of the HMGB subfamily of proteins with roles in promoting proper DNA structure and mediating extracellular inflammation.1,2 It is composed of two HMG box DNA-binding domains and a negatively charged C-terminus.1,3 HMGB1 is ubiquitously expressed and found in the nucleus and extracellular space.1 In the nucleus, it binds DNA and histones and ensures proper DNA structure.3 HMGB1 is secreted by cells in response to regulated cell death pathways, tissue damage, ischemia, organ transplants, or pathogen infection, where it further increases local inflammation and stimulates additional HMGB1 secretion by immune cells.1,2,4 Serum levels of HMGB1 are increased in patients with systemic inflammatory response syndrome (SIRS), a condition characterized by immune system hyperreactivity to infectious and non-infectious stimuli, and a SNP in the promoter region of HMGB1 is associated with poor survival in SIRS patients.5 Cayman's HMGB1 (human, recombinant) protein can be used in binding assays. This protein consists of 225 amino acids and has a calculated molecular weight of 26.21 kDa. By SDS-PAGE, under reducing conditions, the apparent molecular mass of the protein is approximately 33.2 kDa due to glycosylation.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Tang, D., Kang, R., Zeh, H.J., et al. The multifunctional protein HMGB1: 50 years of discovery. Nat. Rev. Immunol. 23(12), 824-841 (2023).

    2. Yang, H., and Tracey, K.J. Targeting HMGB1 in inflammation. Biochim. Biophys. Acta 1799(1-2), 149-156 (2010).

    3. Bianchi, M.E., Beltrame, M., and Paonessa, G. Specific recognition of cruciform DNA by nuclear protein HMG1. Science 243(4894 Pt 1), 1056-1059 (1989).

    4. Ku, S.K., Lee, I.C., Kim, J.A., et al. Anti-septic effects of pellitorine in HMGB1-induced inflammatory responses in vitro and in vivo. Inflammation 37(2), 338-348 (2014).

    5. Kornblit, B., Munthe-Fog, L., Madsen, H.O., et al. Association of HMGB1 polymorphisms with outcome in patients with systemic inflammatory response syndrome. Crit. Care 12(3), R83 (2008).